{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:37Z","timestamp":1781632837621,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Inner Mongolia Medical University Science and Technology Million Project","award":["YKD2020 KJBW (LH) 032"],"award-info":[{"award-number":["YKD2020 KJBW (LH) 032"]}]},{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia Autonomous Region","doi-asserted-by":"publisher","award":["2025MS08152"],"award-info":[{"award-number":["2025MS08152"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]},{"name":"General project of universities directly under Inner Mongolia Autonomous Region","award":["YKD2023MS045"],"award-info":[{"award-number":["YKD2023MS045"]}]},{"name":"Key Laboratory Open Fund Project of Affiliated Hospital of Inner Mongolia Medical University","award":["2022NYFYSYS012"],"award-info":[{"award-number":["2022NYFYSYS012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Gurigumu-13 (GR) was a classical Mongolian medicinal compound widely used in clinical practice for the treatment of non-alcoholic fatty liver disease (NAFLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to investigate the underlying mechanism by which GR exerted its therapeutic effects against NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The main active components of GR were identified using high-resolution mass spectrometry. Using network pharmacology approaches, key targets and potential pathways of GR against NAFLD were predicted and preliminarily validated through molecular docking. Furthermore, transcriptomic sequencing analysis, combined with in vivo and in vitro experiments was performed to elucidate the efficacy and mechanism of GR in alleviating NAFLD. In vivo, a rat model of NAFLD was established by feeding Wistar rats a methionine-choline deficient (MCD) diet. Serum levels of AST, ALT, TC, TG, MDA, GSH, SOD, HDL-C, and LDL-C were measured. Liver tissues were collected for histopathological examination via H&amp;E staining. In vitro, HepG2 cells were treated with oleic acid and palmitic acid to induce lipid accumulation. Intracellular TG content, as well as MDA and SOD levels, were assessed. Lipid deposition was visualized by Oil Red O staining. The expression of relevant genes and proteins was further analyzed by Western blotting and quantitative real-time PCR (qRT-PCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mass spectrometry analysis identified a total of 151 major bioactive compounds in GR. Through network pharmacology, 406 effective active ingredients and 1,012 potential targets of GR were screened. After intersecting with NAFLD-related genes (1,929 genes collected from Genecards and OMIM databases), 329 common targets were obtained. Protein-protein interaction network analysis indicated that STAT3, AKT, and others served as core targets. GO and KEGG enrichment analyses revealed that these genes are primarily involved in biological processes such as oxidative stress and lipid metabolism, as well as signaling pathways including\n                      <jats:italic>PI3K\/AKT<\/jats:italic>\n                      and insulin resistance. In vivo, after 8 weeks of MCD diet feeding, rats in the model group exhibited significant hepatocellular fat accumulation, along with increases in body weight (1.82 times of the control group) and liver index (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). GR intervention ameliorated these pathological changes, reduced serum levels of AST, ALT, TC, TG, MDA, and LDL-C (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), and elevated levels of GSH, SOD, and HDL-C (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). In vitro, GR significantly decreased triglyceride content in lipid-loaded HepG2 cells, alleviated intracellular lipid deposition (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), and reduced the elevated glucose concentration in the culture medium of the model group. Additionally, GR reversed the increase in ROS and MDA contents and the decrease in SOD activity induced by the lipid-accumulation model. Western blotting results demonstrated that GR upregulated the phosphorylation levels of PI3K, AKT, and mTOR, and reduced STAT3 protein expression (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). These changes were further supported by qPCR results (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The improvement of NAFLD by GR may be primarily achieved through its active components (such as ellagic acid and terchebin) via modulation of key targets (such as STAT3) and signaling pathways (such as PI3K\/AKT\/mTOR), thereby regulating lipid metabolism, alleviating oxidative stress and insulin resistance, and exerting therapeutic effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-026-00640-7","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T12:34:22Z","timestamp":1768653262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the biological mechanism of Gurigumu-13 in the treatment of non-alcoholic fatty liver disease based on network pharmacology"],"prefix":"10.1186","volume":"163","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"2","key":"640_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41575-020-00406-0","volume":"18","author":"MF","year":"2021","unstructured":"MF. A nonalcoholic fatty liver disease: another leap forward. Nat Reviews Gastroenterol Hepatol. 2021;18(2):85\u20136.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"640_CR2","doi-asserted-by":"publisher","first-page":"1381712","DOI":"10.3389\/fphar.2024.1381712","volume":"15","author":"ZHENG","year":"2024","unstructured":"ZHENG, S,XUE C,LI S, et al. Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review[J]. Front Pharmacol. 2024;15:1381712.","journal-title":"Front Pharmacol"},{"issue":"3","key":"640_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"M Z Y","year":"2019","unstructured":"Z Y M. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70(3):531\u201344.","journal-title":"J Hepatol"},{"issue":"4","key":"640_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"ZHOU","year":"2019","unstructured":"ZHOU, F,ZHOU J,WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-Analysis. Hepatology (Baltimore MD). 2019;70(4):1119\u201333.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"640_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"POUWELS","year":"2022","unstructured":"POUWELS, S,SAKRAN N,GRAHAM Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disorders. 2022;22(1):63.","journal-title":"BMC Endocr Disorders"},{"issue":"9","key":"640_CR6","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1016\/j.apsb.2022.05.001","volume":"12","author":"JI","year":"2022","unstructured":"JI, L,LI Q,HE, Y, et al. Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug potentilla discolor Bunge. Acta Pharm Sinica B. 2022;12(9):3529\u201347.","journal-title":"Acta Pharm Sinica B"},{"key":"640_CR7","doi-asserted-by":"publisher","first-page":"1033129","DOI":"10.3389\/fnut.2022.1033129","volume":"9","author":"WU","year":"2022","unstructured":"WU, Q,CHEN Z,DING, Y, et al. Protective effect of traditional Chinese medicine on non-alcoholic fatty liver disease and liver cancer by targeting ferroptosis. Front Nutr. 2022;9:1033129.","journal-title":"Front Nutr"},{"issue":"12","key":"640_CR8","doi-asserted-by":"publisher","first-page":"100156","DOI":"10.1016\/j.cjac.2022.100156","volume":"50","author":"YANG","year":"2022","unstructured":"YANG, XUEMIAO,BO YUKUN,YANG, DAN, et al. Investigation of the mechanism of traditional Mongolian medicine Gurigumu-13 pill for treating acetaminophen-induced liver injury using a network Pharmacology and metabolomics approach. Chin J Anal Chem. 2022;50(12):100156.","journal-title":"Chin J Anal Chem"},{"key":"640_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/JIR.S216125","volume":"12","author":"AZIZI M,ABBASI N,MOHAMADPOUR M","year":"2019","unstructured":"AZIZI M,ABBASI N,MOHAMADPOUR M, et al. Investigating the effect of crocus sativus L. petal hydroalcoholic extract on inflammatory and enzymatic indices resulting from alcohol use in kidney and liver of male rats. J Inflamm Res. 2019;12:269\u201383.","journal-title":"J Inflamm Res"},{"key":"640_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijbiomac.2021.12.036","volume":"196","author":"ZHANG","year":"2022","unstructured":"ZHANG, L,WANG Y,WU, F, et al. MDG, an ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila. Int J Biol Macromol. 2022;196:23\u201334.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"640_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1177\/08853282221139132","volume":"37","author":"GUAN","year":"2023","unstructured":"GUAN, Q,ZHOU X,YANG F, et al. A novel strategy against hepatitis B virus: glycyrrhetnic acid conjugated multi-component synergistic nano-drug delivery system for targeted therapy. J Biomater Appl. 2023;37(8):1393\u2013408.","journal-title":"J Biomater Appl"},{"key":"640_CR12","doi-asserted-by":"publisher","first-page":"153479","DOI":"10.1016\/j.phymed.2021.153479","volume":"83","author":"FENG X H,XU H Y,WANG J Y","year":"2021","unstructured":"FENG X H,XU H Y,WANG J Y, et al. In vivo hepatoprotective activity and the underlying mechanism of chebulinic acid from terminalia chebula fruit. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2021;83:153479.","journal-title":"Phytomedicine: Int J Phytotherapy Phytopharmacology"},{"key":"640_CR13","doi-asserted-by":"publisher","first-page":"155241","DOI":"10.1016\/j.phymed.2023.155241","volume":"123","author":"LI","year":"2024","unstructured":"LI, X,CHEN W,REN, J, et al. Effects of Curcumin on non-alcoholic fatty liver disease: A scientific metrogy study. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2024;123:155241.","journal-title":"Phytomedicine: Int J Phytotherapy Phytopharmacology"},{"issue":"1","key":"640_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13105-021-00852-7","volume":"78","author":"ABDOLAHI","year":"2022","unstructured":"ABDOLAHI, A,VAHABZADEH Z,IZADPANAH, E, et al. Vaspin attenuates steatosis-induced fibrosis via GRP78 receptor by targeting AMPK signaling pathway. J Physiol Biochem. 2022;78(1):185\u201397.","journal-title":"J Physiol Biochem"},{"issue":"2","key":"640_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13105-021-00801-4","volume":"77","author":"MOLOUDIMR NOURI H,SHEIKHOLESLAMI-VATANI D","year":"2021","unstructured":"NOURI H,SHEIKHOLESLAMI-VATANI D MOLOUDIMR. Changes in UPR-PERK pathway and muscle hypertrophy following resistance training and creatine supplementation in rats. J Physiol Biochem. 2021;77(2):331\u20139.","journal-title":"J Physiol Biochem"},{"issue":"6","key":"640_CR16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/s41401-021-00786-2","volume":"43","author":"WU Y K,REN Z N,ZHU S L","year":"2022","unstructured":"WU Y K,REN Z N,ZHU S L, et al. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21\/FGFR1 signaling pathway. Acta Pharmacol Sin. 2022;43(6):1473\u201383.","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"640_CR17","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.7150\/ijbs.85883","volume":"19","author":"GUAN Q,WANG Z,HU","year":"2023","unstructured":"GUAN Q,WANG Z,HU, K, et al. Melatonin ameliorates hepatic ferroptosis in NAFLD by inhibiting ER stress via the MT2\/cAMP\/PKA\/IRE1 signaling Pathway. Int J Biol Sci. 2023;19(12):3937\u201350","journal-title":"Int J Biol Sci"},{"issue":"12","key":"640_CR18","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1007\/s11095-023-03631-9","volume":"40","author":"LIU","year":"2023","unstructured":"LIU, Y,VANAERNUM Z,ZHANG, Y, et al. LC-MS approach to Decipher a light chain chromatographic peak splitting of a monoclonal Antibody. Pharm Res. 2023;40(12):3087\u201398.","journal-title":"Pharm Res"},{"issue":"3","key":"640_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/ijms18030620","volume":"18","author":"HONG","year":"2017","unstructured":"HONG, M,LI S,WANG N, et al. A biomedical investigation of the hepatoprotective effect of radix salviae miltiorrhizae and network Pharmacology-Based prediction of the active compounds and molecular Targets. Int J Mol Sci. 2017;18(3):620.","journal-title":"Int J Mol Sci"},{"key":"640_CR20","doi-asserted-by":"publisher","first-page":"e14171","DOI":"10.7717\/peerj.14171","volume":"10","author":"YANG","year":"2022","unstructured":"YANG, R,YANG H,JIANG, D, et al. Investigation of the potential mechanism of the Shugan Xiaozhi Decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular Docking and molecular dynamics simulation. PeerJ. 2022;10:e14171.","journal-title":"PeerJ"},{"issue":"6","key":"640_CR21","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1053\/j.gastro.2018.09.010","volume":"155","author":"LUO","year":"2018","unstructured":"LUO, X,LI H,MA, L, et al. Expression of STING is increased in liver tissues from patients with NAFLD and promotes Macrophage-Mediated hepatic inflammation and fibrosis in Mice. Gastroenterology. 2018;155(6):1971\u201384. e1974.","journal-title":"Gastroenterology"},{"issue":"9","key":"640_CR22","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1080\/15548627.2020.1834711","volume":"17","author":"PARK H S,SONG J W,PARK J H","year":"2021","unstructured":"PARK H S,SONG J W,PARK J H, et al. TXNIP\/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy. 2021;17(9):2549\u201364.","journal-title":"Autophagy"},{"issue":"6","key":"640_CR23","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s11695-017-3065-z","volume":"28","author":"TSUCHIYA","year":"2018","unstructured":"TSUCHIYA, T,NAITOH T,NAGAO M, et al. Increased bile acid signals after Duodenal-Jejunal bypass improve Non-alcoholic steatohepatitis (NASH) in a rodent model of Diet-Induced NASH. Obes Surg. 2018;28(6):1643\u201352.","journal-title":"Obes Surg"},{"issue":"10","key":"640_CR24","doi-asserted-by":"publisher","first-page":"e13612","DOI":"10.1111\/obr.13612","volume":"24","author":"DEMIR M,BORNSTEIN S R,MANTZOROS C S","year":"2023","unstructured":"DEMIR M,BORNSTEIN S R,MANTZOROS C S, et al. Liver fat as risk factor of hepatic and cardiometabolic diseases. Obes Reviews: Official J Int Association Study Obes. 2023;24(10):e13612.","journal-title":"Obes Reviews: Official J Int Association Study Obes"},{"issue":"4","key":"640_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/cbdd.14292","volume":"102","author":"M BAO, L,HAO P,JIANG","year":"2023","unstructured":"BAO, L,HAO P,JIANG M, et al. Liquiritigenin regulates insulin sensitivity and ameliorates inflammatory responses in the nonalcoholic fatty liver by activation PI3K\/AKT pathway. Chem Biol Drug Des. 2023;102(4):793\u2013804.","journal-title":"Chem Biol Drug Des"},{"key":"640_CR26","doi-asserted-by":"publisher","first-page":"115279","DOI":"10.1016\/j.biopha.2023.115279","volume":"165","author":"HE","year":"2023","unstructured":"HE, Y,WANG H,LIN S, et al. Advanced effect of Curcumin and Resveratrol on mitigating hepatic steatosis in metabolic associated fatty liver disease via the PI3K\/AKT\/mTOR and HIF-1\/VEGF cascade. Biomed Pharmacother. 2023;165:115279.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"640_CR27","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.3390\/cells10092475","volume":"10","author":"EL NASHAR E M,ALGHAMDI M A,ALASMARI","year":"2021","unstructured":"EL NASHAR E M,ALGHAMDI M A,ALASMARI W A, et al. Autophagy promotes the survival of adipose mesenchymal Stem\/Stromal cells and enhances their therapeutic effects in Cisplatin-Induced liver injury via modulating TGF-\u03b21\/Smad and PI3K\/AKT signaling Pathways. Cells. 2021;10(9):2475.","journal-title":"Cells"},{"issue":"4","key":"640_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"FRUMAN D A,CHIU H,HOPKINS B D","year":"2017","unstructured":"FRUMAN D A,CHIU H,HOPKINS B D, et al. The PI3K pathway in human Disease. Cell. 2017;170(4):605\u201335.","journal-title":"Cell"},{"issue":"1","key":"640_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"GLAVIANO A,FOO A S C,LAM H Y","year":"2023","unstructured":"GLAVIANO A,FOO A S C,LAM H Y, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"1","key":"640_CR30","doi-asserted-by":"publisher","first-page":"2237209","DOI":"10.1080\/14756366.2023.2237209","volume":"38","author":"HUANG","year":"2023","unstructured":"HUANG, X,YOU L,NEPOVIMOVA E, et al. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK). J Enzyme Inhib Med Chem. 2023;38(1):2237209.","journal-title":"J Enzyme Inhib Med Chem"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00640-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:47:40Z","timestamp":1781632060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00640-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["640"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00640-7","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental protocols in this study were approved by the Medical Ethics Committee of Inner Mongolia Medical University on 14 October 2021 (Ethics approval No. YKD202102054). Procedures were conducted in accordance with the ARRIVE 2.0 guidelines and the requirements of EU Directive 2010\/63\/EU. A total of 40 male Wistar rats (180\u2013200\u00a0g) were used. They were housed in the Laboratory Animal Center of Inner Mongolia Medical University (License No. SCXK(M) 2020-0001). This strain, characterized by a clear genetic background and high reproducibility, is the preferred model for studying metabolic disorders in this project. Animals were maintained in an SPF barrier facility under a 12-h light\/dark cycle with ad libitum access to food and water.All surgical procedures were performed under anesthesia with 2% sodium pentobarbital (50\u00a0mg kg\u207b\u00b9, i.p.). Post-operative analgesia was provided with buprenorphine (0.1\u00a0mg kg\u207b\u00b9, s.c.) every 12\u00a0h for 48\u00a0h. Body weight, posture, and food intake were monitored at 4\u00a0h, 24\u00a0h, and 48\u00a0h after surgery. Pain was assessed using a 0\u20134 scale; scores\u2009\u2265\u20093 prompted additional analgesia or early euthanasia. The humane endpoint was defined as \u2265\u200920% body-weight loss or inability to feed. Euthanasia was performed by gradual CO\u2082 inhalation (20% chamber volume min\u207b\u00b9) until respiratory arrest, followed by cervical dislocation to confirm death. Blood was collected from the retro-orbital venous plexus, with no more than 10% of total blood volume removed per collection and a minimum interval of 2 weeks between samplings. No exemptions were requested; all procedures underwent full ethical review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}